Known targets — ChEMBL curated mechanism
ABL1BMXBRAFBTKCHRNA4CHRNB2CSNK1EEGFRERBB2F10FLT1FLT3FLT4IGF1RINSRITKJAK3KDRKITOPRM1PARP1PARP2PDGFRBPIK3CDRAF1RETSLC18A2TECTXKdacAdacBdacCftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 known ✓ | P35372 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | HTR6 | P50406 | 1/20 | 0.51 |
| ▸ | BCHE | P06276 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | ACHE | P22303 | 4/20 | 0.48 |
| ▸ | BACE1 | P56817 | 3/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.45 |
| ▸ | SPHK1 | Q9NYA1 | 2/20 | 0.45 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.45 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.45 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5743817 | 0.91 | SMN1; SMN2 (0.51) | SMN1; SMN2HTR6BCHEALDH1A1LMNA | |
| SCHEMBL5745073 | 0.91 | FUCA1 (0.50) | SMN1; SMN2HTR6BCHEALDH1A1LMNA | |
| SCHEMBL6982309 | 0.89 | ALDH1A1 (0.57) | SMN1; SMN2HTR6BCHEALDH1A1LMNA | |
| SCHEMBL5744519 | 0.89 | ALDH1A1 (0.57) | SMN1; SMN2HTR6BCHEALDH1A1LMNA | |
| SCHEMBL5745819 | 0.89 | ALDH1A1 (0.57) | SMN1; SMN2HTR6BCHEALDH1A1LMNA | |
| SCHEMBL5745121 | 0.88 | ALDH1A1 (0.54) | SMN1; SMN2BCHEALDH1A1ACHEBACE1 | |
| SCHEMBL5744568 | 0.87 | SMN1; SMN2 (0.58) | SMN1; SMN2HTR6ALDH1A1LMNATSHR | |
| SCHEMBL5746062 | 0.85 | LMNA (0.53) | SMN1; SMN2HTR6BCHEALDH1A1LMNA | |
| SCHEMBL736286 | 0.85 | ALDH1A1 (0.62) | BCHEALDH1A1ACHEBACE1FUCA1 | |
| SCHEMBL736285 | 0.85 | ALDH1A1 (0.62) | BCHEALDH1A1ACHEBACE1FUCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1686130-B1 | Pyrrolo[2,3-d]pyrimidine compounds as immunosuppressive agents | PFIZER PROD INC (US) | 2009-02-18 | — | — | EP | disclosed |
| US-20070161666-A1 | Pyrrolo[2,3-d]pyrimidine compounds | PFIZER INC | 2007-07-12 | — | — | US | disclosed |
| US-7192963-B2 | Pyrrolo[2,3-d]pyrimidine compounds | PFIZER INC (US) | 2007-03-20 | — | — | US | disclosed |
| EP-1288198-B1 | PROCESS FOR THE PRODUCTION OF SULFONIC ESTERS | KANEKA CORP (JP) | 2006-12-20 | — | — | EP | disclosed |
| EP-1686130-A1 | Pyrrolo[2,3-d]pyrimidine compounds as immunosuppressive agents | Pfizer Products Incorporated (US) | 2006-08-02 | — | — | EP | disclosed |
| EP-1294724-B1 | PYRROLO¬2,3-D|PYRIMIDINE COMPOUNDS AS IMMUNOSUPPRESSIVE AGENTS | PFIZER PROD INC (US) | 2006-04-19 | — | — | EP | disclosed |
| US-6992205-B2 | Process for the production of sulfonic esters | KANEKA CORPORATION (JP) | 2006-01-31 | — | — | US | disclosed |
| US-6962993-B2 | Pyrrolo[2,3-d]pyrimidine compounds | PFIZER INC. (US) | 2005-11-08 | — | — | US | disclosed |
| US-20050197349-A1 | Pyrrolo[2,3-D]pyrimidine compounds | PFIZER INC. | 2005-09-08 | — | — | US | disclosed |
| US-6864372-B2 | Process for the production of sulfonic esters | KANEKA CORPORATION (JP) | 2005-03-08 | — | — | US | disclosed |
| US-6794519-B2 | Process for the production of sulfonic esters | KANEKA CORPORATION (JP) | 2004-09-21 | — | — | US | disclosed |
| US-6696567-B2 | INHIBITION OF PROTEIN KINASES OR JANUS KINASE 3; TREATING OR PREVENTING ORGAN TRANSPLANT REJECTION, XENO TRANSPLATION, LUPUS, MULTIPLE SCLEROSIS, RHEUMATOID ARTHRITIS, PSORIASIS, TYPE I DIABETES OR VARIOUS DISEASE COMPLICATIONS | PFIZER INC. | 2004-02-24 | — | — | US | disclosed |
| US-20030220353-A1 | Pyrrolo[2,3-d]pyrimidine compounds | PFIZER INC. | 2003-11-27 | — | — | US | disclosed |
| US-20030176713-A1 | Reacting an amino alcohol derivative with organic sulfonyl halide in a mixed solvent composed of an aprotic organic solvent and water in presence of a non-water prohibiting inorganic base | KANEKA CORPORATION (JP) | 2003-09-18 | — | — | US | disclosed |
| US-20030176711-A1 | Process for the production of sulfonic esters | KANEKA CORPORATION (JP) | 2003-09-18 | — | — | US | disclosed |
| US-20030162966-A1 | PROCESS FOR THE PRODUCTION OF SULFONIC ESTERS | KANEKA CORPORATION (JP) | 2003-08-28 | — | — | US | disclosed |
| EP-1294724-A1 | PYRROLO[2,3-D]PYRIMIDINE COMPOUNDS AS IMMUNOSUPPRESSIVE AGENTS | Pfizer Products Inc. (US) | 2003-03-26 | — | — | EP | disclosed |
| EP-1288198-A1 | PROCESS FOR THE PRODUCTION OF SULFONIC ESTERS | KANEKA CORPORATION (JP) | 2003-03-05 | — | — | EP | disclosed |
| US-20020068746-A1 | Pyrrolo[2,3-d]pyrimidine compounds | PFIZER INC. | 2002-06-06 | — | — | US | disclosed |
| WO-2002000661-A1 | PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS AS IMMUNOSUPPRESSIVE AGENTS | PFIZER PRODUCTS INC. (US) | 2002-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162966-A1 | PROCESS FOR THE PRODUCTION OF SULFONIC ESTERS | TST, STS, SELENOI | OPRM1 2799/4885SMN1; SMN2 1882/4885HTR6 4175/4885 |
| US-20030220353-A1 | Pyrrolo[2,3-d]pyrimidine compounds | JAK1, CDK2, JAK3 | OPRM1 2699/4885SMN1; SMN2 4219/4885HTR6 4421/4885 |
| US-20050197349-A1 | Pyrrolo[2,3-D]pyrimidine compounds | CDK2, CDK3, JAK3 | OPRM1 3379/4885SMN1; SMN2 4335/4885HTR6 4304/4885 |
| US-20020068746-A1 | Pyrrolo[2,3-d]pyrimidine compounds | JAK1, CDK2, JAK3 | OPRM1 2699/4885SMN1; SMN2 4219/4885HTR6 4421/4885 |
| US-20030176711-A1 | Process for the production of sulfonic esters | TST, STS, SELENOI | OPRM1 2799/4885SMN1; SMN2 1882/4885HTR6 4175/4885 |
| US-20070161666-A1 | Pyrrolo[2,3-d]pyrimidine compounds | CDK2, CDK3, JAK3 | OPRM1 3379/4885SMN1; SMN2 4335/4885HTR6 4304/4885 |
| US-20030176713-A1 | Reacting an amino alcohol derivative with organic sulfonyl halide in a mixed solvent composed of an aprotic organic solvent and water in presence of a non-water prohibiting inorganic base | BRAF, ADH1C, TST | OPRM1 1372/4885SMN1; SMN2 1828/4885HTR6 3839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.